How India is Adopting Decentralized Trials: Opportunities, Challenges, and Regulatory Evolution

Introduction

Decentralized Clinical Trials (DCTs) are reshaping the global clinical research ecosystem by bringing trials directly to patients through digital technologies, remote monitoring, and home healthcare. In India, the adoption of DCTs gained momentum during the COVID-19 pandemic, when restrictions on movement and in-person site visits disrupted traditional site-based research. With India being home to a vast and diverse patient population, the potential for implementing DCT models—especially in underserved and rural areas—is immense.

India’s clinical research ecosystem is transitioning toward hybrid and decentralized models. Regulatory agencies such as CDSCO and ethical bodies like ICMR are beginning to evaluate the framework for digitally enabled trials, remote informed consent, and telemedicine integration. This article provides a comprehensive overview of how India is embracing decentralized trials, the evolving regulatory environment, and practical considerations for successful implementation.

Regulatory Framework and Evolution

CDSCO’s Position on DCTs

While the CDSCO has not yet published a formal DCT-specific guidance document akin to the US FDA’s or EMA’s, it has shown increasing openness to digital health innovations. During the pandemic, CDSCO permitted flexible measures, such as teleconsultations, remote monitoring visits, and home sample collection, for ongoing trials. These allowances set a de facto regulatory precedent for DCT elements in India.

ICMR’s Ethical Guidelines and Telemedicine Policy

The Indian Council of Medical Research (ICMR) in its 2017 National Ethical Guidelines emphasized patient autonomy, informed consent, and equitable access. In March 2020, the Government of India released the Telemedicine Practice Guidelines, co-developed by MoHFW and NITI Aayog. These guidelines support physician-patient virtual consultations and provide a framework for integrating remote interactions into clinical studies.

NDCTR 2019 and DCT Flexibility

The New Drugs and Clinical Trials Rules (NDCTR), 2019 do not prohibit decentralized elements. While structured around site-based trials, they are flexible enough to accommodate hybrid models, provided sponsors maintain patient safety, data integrity, and protocol compliance. Ethics Committees play a vital role in evaluating digital tools, eConsent platforms, and risk mitigation measures.

Core Clinical Trial Insights: Decentralized Models in Indian Context

Hybrid vs Fully Decentralized Trials

Most Indian trials are currently adopting a hybrid model—blending in-person visits for critical assessments with remote monitoring and virtual follow-ups. Fully decentralized models are rare due to infrastructure gaps and regulatory caution. However, CROs and sponsors are increasingly piloting fully remote protocols in dermatology, psychiatry, and wellness trials.

Key Decentralized Trial Components Being Piloted in India

• eConsent: Platforms enabling remote informed consent via video call and digital signature.
• Telemedicine Visits: Replacing physical site visits with virtual consultations and digital diaries.
• Home Sample Collection: Trained phlebotomists visit patients at home for blood draws and swabs.
• Wearable Devices: Collecting real-time health data (e.g., heart rate, glucose) from trial subjects.
• Direct-to-Patient (DTP) Drug Supply: Investigational products shipped to patient homes with remote monitoring.
• Remote SDV (Source Data Verification): Monitors access scanned or EMR-based source documents.

Infrastructure Challenges and Workarounds

India’s diverse geography and digital divide create unique challenges for DCTs:

• Connectivity Issues: In rural areas, poor internet limits virtual visits and eConsent processes.
• Digital Literacy: Older populations or those in underserved areas may struggle with apps and devices.
• Data Security: Compliance with India’s IT Act and the new DPDP Act (2023) is critical for patient privacy.

To address these issues, sponsors are deploying hybrid models with local facilitators—such as village health workers—to assist with digital tools, teleconsultation access, and wearable setup.

CROs and Site Readiness

Contract Research Organizations (CROs) are investing in DCT infrastructure, such as EDC systems, eConsent platforms, and virtual PI oversight. Leading CROs like Syneos, IQVIA, and Indian firms such as Cliantha and Veeda are conducting DCT pilots with global sponsors.

Sites are also adapting to remote monitoring and virtual PI visits. However, there remains a significant need for capacity building, SOP creation, and staff training around GCP compliance in decentralized settings.

Patient Recruitment and Retention in DCTs

DCTs are enabling access to patients who would otherwise be excluded from trials due to distance or mobility issues. Digital advertisements, SMS-based recruitment, and AI-based pre-screening are being used to improve outreach. Retention is managed through remote check-ins, electronic patient diaries, and gamified engagement tools.

Best Practices and Preventive Measures

• Engage Ethics Committees early to validate eConsent and telemedicine tools.
• Ensure backup site visits for technology failure scenarios.
• Use multi-language video explainers to improve eConsent comprehension.
• Maintain GCP-compliant audit trails for remote activities.
• Develop SOPs for home visits, drug delivery, and remote SAE reporting.

Scientific and Regulatory Evidence

• US FDA’s DCT Guidance (2023 Draft) – Serves as a global benchmark.
• EMA Reflection Paper on DCTs – Cites operational and ethical best practices.
• ICMR Ethical Guidelines (2017) – Reference for informed consent and digital tools.
• Telemedicine Practice Guidelines (2020) – Indian foundation for virtual consults.
• DPDP Act, 2023 – Regulates digital data protection and patient privacy.

Special Considerations in Indian DCTs

Data Privacy Compliance

With India’s new Digital Personal Data Protection (DPDP) Act, 2023, sponsors must ensure that electronic data collection tools have adequate security features, encryption, and consent management protocols. Data storage localization and breach notification mechanisms are also essential.

Rural and Underserved Populations

Decentralization opens doors to populations historically underrepresented in trials. However, additional measures are needed to ensure ethical inclusion—like translated consent, local support staff, and simplified device interfaces.

Adverse Event Management

Protocols must clearly define how adverse events are reported, monitored, and managed in a remote setting. Sites must establish 24×7 helplines and emergency referral pathways.

When Sponsors Should Seek Regulatory Advice

• Before using eConsent, remote PI oversight, or wearable integration.
• When including vulnerable populations like elderly or pediatric patients in DCTs.
• For approval of home-based procedures or telemedicine-driven endpoints.
• When conducting fully remote or cross-border trials requiring import/export of IP.

FAQs

1. Are decentralized trials legally allowed in India?

Yes, though not explicitly defined under NDCTR, decentralized components are being piloted under regulatory oversight, especially post-COVID.

2. Is eConsent permitted for Indian trials?

Yes, provided Ethics Committees approve the process and platforms are secure, validated, and GCP-compliant.

3. Can patients in rural areas participate in DCTs?

Yes. Sponsors can deploy local facilitators and use hybrid models to reach underserved areas with limited digital infrastructure.

4. What trials are best suited for DCT in India?

Studies in dermatology, psychiatry, metabolic diseases, and rare diseases are most suited due to minimal need for in-person assessments.

5. What are key risks in DCTs?

Data breaches, protocol non-adherence, miscommunication, and inadequate adverse event capture are key risks requiring strong mitigation planning.

6. Does CDSCO require additional approvals for DCT tools?

Currently, no formal additional approvals are mandated, but protocol amendments must detail decentralized elements and receive Ethics Committee clearance.

7. Are Indian CROs prepared for DCTs?

Leading CROs are investing in DCT capabilities. However, smaller CROs and sites still require training and systems upgrades.

Conclusion

Decentralized clinical trials offer immense potential for transforming India’s clinical research ecosystem by improving accessibility, patient-centricity, and trial efficiency. While the regulatory framework continues to evolve, proactive engagement with Ethics Committees, adherence to GCP standards, and strategic investment in digital tools can ensure successful implementation of DCTs in India. Sponsors who embrace this shift today will be better positioned for the future of global clinical research.

Transformation of Clinical Trials in India During and After COVID-19

Introduction

The COVID-19 pandemic dramatically disrupted the global clinical research ecosystem. India, with its vast patient population and growing footprint in global drug development, experienced a cascade of challenges and adaptations across trial operations. From recruitment slowdowns and lockdown-induced site closures to the rapid digitization of processes, clinical trials in India underwent profound structural and regulatory changes during the pandemic.

With India emerging as a hub for vaccine trials and COVID-19 treatment research, agencies like the Central Drugs Standard Control Organization (CDSCO) and the Indian Council of Medical Research (ICMR) responded with unprecedented agility. The introduction of virtual site visits, remote monitoring, electronic informed consent, and accelerated approvals reshaped the conduct of clinical trials in the country.

This article explores how COVID-19 has reshaped clinical trial operations in India, drawing on real-world regulatory responses, decentralized trial models, and evolving industry practices that may permanently alter India’s clinical research landscape.

Background / Regulatory Framework

CDSCO and NDCTR 2019 Flexibilities During COVID-19

Although the New Drugs and Clinical Trials Rules (NDCTR) 2019 did not explicitly anticipate a pandemic, CDSCO issued multiple advisories starting in March 2020 to enable the continuation of critical trials. Some of the regulatory adaptations included:

• Relaxed visit schedules and permitted remote data capture
• Virtual Ethics Committee meetings
• Conditional waivers on protocol deviations reporting
• Accelerated review for COVID-19 specific studies
• Emergency Use Authorizations (EUAs) for vaccines and therapeutics

ICMR and Ministry of Health Initiatives

The Indian Council of Medical Research (ICMR) played a pivotal role in trial prioritization and development of national guidance for COVID-19 vaccine trials. Highlights include:

• Frameworks for fast-track approvals for repurposed drugs
• Support for setting up large-scale vaccine trials in partnership with academia and industry
• Development of standard COVID-specific trial protocols

CTRI and Registration Transparency

During the pandemic, the Clinical Trials Registry – India (CTRI) made updates to ensure trial registration data clearly reflected COVID-19-related studies, timelines, and site disruptions.

Core Clinical Trial Insights

1. Disruption of Site Operations and Patient Visits

The nationwide lockdown in India starting March 24, 2020 led to immediate halts in recruitment, follow-up visits, and site monitoring. Challenges included:

• Suspension of non-COVID trials in hospitals handling COVID care
• Participants unable to travel for follow-ups or dosing
• Investigational product storage and handling disruptions
• High loss-to-follow-up in long-term studies

These issues triggered the need for remote site interactions and decentralized alternatives.

2. Rise of Decentralized Trial Models

Decentralized Clinical Trials (DCTs) gained traction, particularly in urban centers. Adoption included:

• Telemedicine consultations and virtual follow-ups
• Courier shipment of investigational products to homes
• Use of mobile health devices for data capture
• Electronic Patient-Reported Outcomes (ePRO)

While DCT adoption was uneven due to digital access gaps, it became a critical enabler in metropolitan areas like Mumbai, Bengaluru, and Hyderabad.

3. Remote Monitoring and Virtual Site Visits

With sponsor staff unable to visit trial sites, CDSCO permitted remote monitoring. CROs and sponsors adopted platforms like:

• Secure web-based document sharing (eTMF, EDC access)
• Teleconferences and live video audits
• Photographic verification of IP storage logs

This trend led to increased investment in digital infrastructure at investigator sites and permanent inclusion of hybrid monitoring in SOPs.

4. Accelerated Vaccine and Therapeutic Trials

India hosted major COVID-19 vaccine trials, including for:

• COVAXIN (Bharat Biotech – ICMR)
• COVISHIELD (Serum Institute – Oxford-AstraZeneca)
• Sputnik V, ZyCoV-D, and Corbevax trials

CDSCO granted restricted emergency use authorizations (EUAs) under special conditions, including rolling data submissions and post-marketing safety monitoring (Phase IV commitments).

5. Changes in Ethics Committee Operations

Due to movement restrictions, CDSCO permitted virtual Ethics Committee (EC) meetings using tools like Zoom or Webex. ECs were required to:

• Maintain detailed minutes and recordings
• Expedite COVID-related approvals
• Use digital signature systems for review forms

This digital transition is likely to persist post-COVID for efficiency reasons.

6. Regulatory Guidance and Protocol Flexibility

CDSCO issued multiple guidance notes encouraging sponsors and investigators to:

• Document protocol deviations with justification
• Ensure participant safety via alternative assessments
• Inform ECs about all procedural changes

Risk-based monitoring and site audits were prioritized only for essential studies, especially those with public health relevance.

7. Clinical Trial Supply Chain Adaptations

Transport disruptions during lockdown necessitated major supply chain adjustments:

• Direct-to-patient (DTP) IP delivery with temperature-controlled packaging
• Centralized IP warehousing for multicenter trials
• Relaxed timelines for IMP accountability records

8. Recruitment and Retention Challenges

Non-COVID trials saw significant recruitment drop (40–70%) due to:

• Public fear of hospital visits
• Reduced site capacity and reallocation of medical staff
• Difficulty conducting screening procedures

Retention strategies included home visits, remote contact, and milestone-based engagement through digital tools.

9. Regulatory Timelines and Fast-Tracking

CDSCO fast-tracked reviews for COVID-19 trials, compressing review cycles from 90 days to less than 30 in urgent cases. Priority was given to:

• COVID vaccine and therapeutic trials
• Repurposing of existing drugs
• Post-exposure prophylaxis and diagnostic kits

Best Practices & Preventive Measures

• Develop hybrid protocols with built-in virtual visit contingencies
• Ensure digital consent tools are linguistically and culturally appropriate
• Strengthen CRO-site communication through SOPs on remote monitoring
• Establish clear IP shipment SOPs and temperature excursion logs
• Train EC members on remote protocol review procedures

Scientific & Regulatory Evidence

• CDSCO advisories issued March–November 2020
• NDCTR 2019 Section 2(zx) on emergency approvals
• ICMR trial guidelines for COVID vaccine studies
• WHO Solidarity trial operational guidance
• CTRI data on registered COVID studies (2020–2022)

Special Considerations

1. Urban vs Rural Disparities

Digital trial tools were primarily usable in urban zones. Rural India faced issues of poor internet access, limiting decentralized trial expansion.

2. Pediatric Trial Readiness Post-COVID

Following adult vaccine success, India launched pediatric vaccine trials (12–18 years, then 6–12). Regulatory expectations around safety monitoring for pediatric studies were heightened post-pandemic.

3. Digital Fatigue and Oversight Gaps

Excessive reliance on virtual monitoring risked missing nuanced site-level issues. SOP revisions post-pandemic now include hybrid monitoring approaches to counterbalance these limitations.

When Sponsors Should Seek Regulatory Advice

• When converting on-site trials into hybrid or decentralized formats
• If seeking EUAs or rolling reviews for public health emergencies
• For implementing eConsent and remote assessments across states
• For vaccine trials in pediatric or high-risk populations
• When initiating large-scale virtual site feasibility or remote SIVs

FAQs

1. Are remote monitoring and virtual EC meetings still allowed in India?

Yes, CDSCO continues to permit hybrid monitoring and virtual EC meetings if appropriately documented and justified.

2. What was the regulatory basis for emergency use approvals during COVID-19?

Section 2(zx) of NDCTR 2019 enabled CDSCO to fast-track critical trial applications and grant restricted emergency approvals.

3. Were decentralized trials legally recognized in India?

While not explicitly codified, CDSCO issued functional permissions for remote visits, ePROs, and DTP delivery through guidance circulars.

4. How were protocol deviations handled during COVID-19?

Sites were required to document all deviations, inform the EC, and provide safety justifications. Many ECs allowed retrospective approvals in emergencies.

5. Did COVID-19 trials improve India’s global standing in clinical research?

Yes. India demonstrated rapid scale-up capacity, operational resilience, and regulatory responsiveness, particularly in vaccine development.

Conclusion

COVID-19 was a turning point for India’s clinical trial ecosystem. What began as a disruption led to accelerated digitalization, decentralized trial models, and streamlined regulatory pathways. Many of these changes — remote monitoring, hybrid site visits, digital consent — are here to stay and will define the next era of clinical research operations in India.